Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04708821 · ClinicalTrials.gov registry record · Phase 4
DEXTENZA Therapy for Treatment of Allergic Conjunctivitis
A Phase 4 study of Bilateral Conjunctivitis (Disorder), sponsored by Clinical Research Center of Florida.
- Completed
- Registry status
- Phase 4
- Development phase
- 31
- Enrollment target
- 1
- Study location
NCT04708821: Completed Phase 4 study of Bilateral Conjunctivitis (Disorder), sponsored by Clinical Research Center of Florida.
NCT04708821 is a Phase 4 study of Bilateral Conjunctivitis (Disorder) that has completed, run by Clinical Research Center of Florida. The registered enrollment target is 31 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04708821, a Phase 4 study of Bilateral Conjunctivitis (Disorder), has completed, sponsored by Clinical Research Center of Florida.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 31 participants
- Enrollment target
- 1
- Study location
Study Summary
This prospective, open-label, single-center, randomized, investigator-sponsored clinical study seeks to compare patient-reported and clinical outcomes with DEXTENZA versus topical steroid or antihistamine treatment in patients with allergic conjunctivitis
Primary Outcome
Patient-reported treatment preference of self-administered topical therapy versus physician-administered therapy at Day 30 (final visit)
Conditions Studied
Interventions
- DRUG olopatadine hydrochloride ophthalmic solution 0.7%
- DRUG Dexamethasone ophthalmic insert 0.4Mg
- DRUG 0.2% loteprednol etabonate ophthalmic suspension
Study Locations (1)
Florida
- Clinical Research Center of Florida - Pompano Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2021-04-30 |
| Est. Completion | 2021-09-02 |
| Phase | Phase 4 |
What the finished NCT04708821 record still lists
NCT04708821 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Bilateral Conjunctivitis (Disorder) appearing as the primary indexed condition, and to 3 interventions - of which olopatadine hydrochloride ophthalmic solution 0.7% is the first listed.
NCT04708821 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT04708821 about?
NCT04708821 is a clinical study titled "DEXTENZA Therapy for Treatment of Allergic Conjunctivitis". This prospective, open-label, single-center, randomized, investigator-sponsored clinical study seeks to compare patient-reported and clinical outcomes with DEXTENZA versus topical steroid or antihistamine treatment in patients with allergic conjunctivitis
What is the current status of trial NCT04708821?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 31 participants. The study started on 2021-04-30. Estimated completion is 2021-09-02.
What conditions does trial NCT04708821 study?
This clinical trial studies the following conditions: Bilateral Conjunctivitis (Disorder).
What interventions are being tested in trial NCT04708821?
The interventions under investigation include: olopatadine hydrochloride ophthalmic solution 0.7% (DRUG), Dexamethasone ophthalmic insert 0.4Mg (DRUG), 0.2% loteprednol etabonate ophthalmic suspension (DRUG).
Who is sponsoring clinical trial NCT04708821?
This trial is sponsored by Clinical Research Center of Florida, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04708821 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04708821's enrollment target sits among peer trials
31 1544th of 2000 higher than 449 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI